These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25308921)

  • 1. Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C.
    Nielsen MJ; Veidal SS; Karsdal MA; Ørsnes-Leeming DJ; Vainer B; Gardner SD; Hamatake R; Goodman ZD; Schuppan D; Patel K
    Liver Int; 2015 Feb; 35(2):429-37. PubMed ID: 25308921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C.
    Hansen JF; Juul Nielsen M; Nyström K; Leeming DJ; Lagging M; Norkrans G; Brehm Christensen P; Karsdal M
    Scand J Gastroenterol; 2018 Jan; 53(1):83-87. PubMed ID: 29069995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Turnover of type III collagen reflects disease severity and is associated with progression and microinflammation in patients with IgA nephropathy.
    Genovese F; Boor P; Papasotiriou M; Leeming DJ; Karsdal MA; Floege J
    Nephrol Dial Transplant; 2016 Mar; 31(3):472-9. PubMed ID: 26311218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunodetection of collagen types I, II, III, and IV for differentiation of liver fibrosis stages in patients with chronic HCV.
    Attallah AM; Mosa TE; Omran MM; Abo-Zeid MM; El-Dosoky I; Shaker YM
    J Immunoassay Immunochem; 2007; 28(2):155-68. PubMed ID: 17424834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury.
    Nielsen MJ; Karsdal MA; Kazankov K; Grønbaek H; Krag A; Leeming DJ; Schuppan D; George J
    Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1242-1252. PubMed ID: 27696451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART.
    Dold L; Nielsen MJ; Praktiknjo M; Schwarze-Zander C; Boesecke C; Schierwagen R; Mohr R; Wasmuth JC; Jansen C; Bischoff J; Rockstroh JK; Karsdal MA; Spengler U; Trebicka J; Leeming DJ
    PLoS One; 2019; 14(7):e0219526. PubMed ID: 31295293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis.
    Thorburn D; Leeming DJ; Barchuk WT; Wang Y; Lu X; Malkov VA; Ito KL; Bowlus CL; Levy C; Goodman Z; Karsdal MA; Muir AJ; Xu J
    Hepatol Commun; 2024 Jul; 8(7):. PubMed ID: 38967589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients.
    Nielsen MJ; Kazankov K; Leeming DJ; Karsdal MA; Krag A; Barrera F; McLeod D; George J; Grønbæk H
    PLoS One; 2015; 10(9):e0137302. PubMed ID: 26406331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum and urine markers of collagen degradation reflect renal fibrosis in experimental kidney diseases.
    Papasotiriou M; Genovese F; Klinkhammer BM; Kunter U; Nielsen SH; Karsdal MA; Floege J; Boor P
    Nephrol Dial Transplant; 2015 Jul; 30(7):1112-21. PubMed ID: 25784725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.
    Laursen TL; Villesen IF; Leeming DJ; Karsdal MA; Sølund C; Tarp B; Kristensen LH; Holmboe CH; Leutscher P; Laursen AL; Gudmann NS; Grønbaek H
    J Viral Hepat; 2021 Feb; 28(2):236-244. PubMed ID: 33058390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of liver fibrosis progression and regression by a serological collagen turnover profile.
    Karsdal MA; Hjuler ST; Luo Y; Rasmussen DGK; Nielsen MJ; Holm Nielsen S; Leeming DJ; Goodman Z; Arch RH; Patel K; Schuppan D
    Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G25-G31. PubMed ID: 30160980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.
    Patel K; Tillmann HL; Matta B; Sheridan MJ; Gardner SD; Shackel NA; McHutchison JG; Goodman ZD
    Aliment Pharmacol Ther; 2016 Feb; 43(3):356-63. PubMed ID: 26560052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy.
    Karsdal MA; Henriksen K; Nielsen MJ; Byrjalsen I; Leeming DJ; Gardner S; Goodman Z; Patel K; Krag A; Christiansen C; Schuppan D
    Am J Physiol Gastrointest Liver Physiol; 2016 Dec; 311(6):G1009-G1017. PubMed ID: 27765759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.
    Vergniol J; Foucher J; Terrebonne E; Bernard PH; le Bail B; Merrouche W; Couzigou P; de Ledinghen V
    Gastroenterology; 2011 Jun; 140(7):1970-9, 1979.e1-3. PubMed ID: 21376047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis.
    Jessen H; Hoyer N; Prior TS; Frederiksen P; Karsdal MA; Leeming DJ; Bendstrup E; Sand JMB; Shaker SB
    Respir Res; 2021 Jul; 22(1):205. PubMed ID: 34261485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C.
    Park SH; Kim CH; Kim DJ; Suk KT; Park JH; Cheong JY; Cho SW; Hwang SG; Lee YJ; Cho M; Yang JM; Park HY; Kim YB
    Clin Biochem; 2011 Dec; 44(17-18):1396-9. PubMed ID: 21971609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease.
    Trépo E; Potthoff A; Pradat P; Bakshi R; Young B; Lagier R; Moreno C; Verset L; Cross R; Degré D; Lemmers A; Gustot T; Berthillon P; Rosenberg W; Trépo C; Sninsky J; Adler M; Wedemeyer H
    J Hepatol; 2011 Jul; 55(1):38-44. PubMed ID: 21145859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values.
    Lichtinghagen R; Pietsch D; Bantel H; Manns MP; Brand K; Bahr MJ
    J Hepatol; 2013 Aug; 59(2):236-42. PubMed ID: 23523583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum fibrosis markers in diagnosing liver fibrosis].
    Liu J; Wang JY; Lu Y
    Zhonghua Nei Ke Za Zhi; 2006 Jun; 45(6):475-7. PubMed ID: 16831325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients.
    Christensen C; Bruden D; Livingston S; Deubner H; Homan C; Smith K; Oh E; Gretch D; Williams J; McMahon B
    J Viral Hepat; 2006 Oct; 13(10):652-8. PubMed ID: 16970596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.